Lanean...
Synthesized OVA(323-339)MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells
BACKGROUND: Antigen-specific immunotherapy (SIT) has been widely practiced in treating allergic diseases such as asthma. However, this therapy may induce a series of allergic adverse events during treatment. Peptide immunotherapy (PIT) was explored to overcome these disadvantages. We confirmed that...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3472185/ https://ncbi.nlm.nih.gov/pubmed/22769043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2172-13-34 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|